还有眼光和见识的CE_老虎社区_美港股上老虎

还有眼光和见识的CEO。

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":489477155615168,"tweetId":"489477155615168","gmtCreate":1760528839503,"gmtModify":1760528841706,"author":{"id":3447258680782140,"idStr":"3447258680782140","authorId":3447258680782140,"authorIdStr":"3447258680782140","name":"自由财富之路","avatar":"https://static.tigerbbs.com/1cdc53929b69f8b806e35f1372121ca4","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":8,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":10,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"html":"<html><head></head><body><p>还有眼光和见识的CEO。</p></body></html>","htmlText":"<html><head></head><body><p>还有眼光和见识的CEO。</p></body></html>","text":"还有眼光和见识的CEO。","highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/489477155615168","repostId":2575513203,"repostType":2,"repost":{"id":"2575513203","kind":"news","pubTimestamp":1760511620,"share":"https://www.laohu8.com/m/news/2575513203?lang=&edition=full","pubTime":"2025-10-15 15:00","market":"hk","language":"zh","title":"辉瑞(PFE.US)CEO呼吁：美国制药业需要与中国合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2575513203","media":"智通财经","summary":"智通财经APP获悉，辉瑞首席执行官阿尔伯特·布尔拉周二表示，美国制药业需要与中国制药业开展合作。此番表态正值美国总统特朗普对主要经济竞争对手中国实施一系列关税措施之际。美国众议院去年也曾通过法案试图限制美国企业与中国药企合作。今年初，辉瑞与中国三生制药达成协议，以12.5亿美元预付款加最高48亿美元里程碑付款的条件，获得一款实验性癌症疗法的授权。","content":"<html><body><p>智通财经APP获悉，<a href=\"https://laohu8.com/S/PFE\">辉瑞</a>(PFE.US)首席执行官阿尔伯特·布尔拉周二表示，美国制药业需要与中国制药业开展合作。过去十年间，中国凭借高效的研发流程使其在全球药物研发中的占比跃升至30%。</p><p>布尔拉在纽约出席美中关系全国委员会晚宴时指出：\"在生物制药领域，中国惊人的速度、成本和规模优势已引发全球竞争格局转变。\"他透露，中国目前拥有约1200种新药候选药物，而十年前这一数字仅为60种。</p><p>此番表态正值美国总统特朗普对主要经济竞争对手中国实施一系列关税措施之际。这些针对<a href=\"https://laohu8.com/S/SBAY\">数百亿</a>美元进口商品的关税政策，据称旨在缩小巨额贸易逆差、重振制造业并打击芬太尼贸易。</p><p>美国众议院去年也曾通过法案试图限制美国企业与中国药企合作。该法案最终未获参议院通过，但今年早些时候已有新版本被重新提交。</p><p>尽管中美存在贸易摩擦，欧美制药公司仍寄望中国补充其药物研发管线。今年初，辉瑞与中国<a href=\"https://laohu8.com/S/01530\">三生制药</a>达成协议，以12.5亿美元预付款加最高48亿美元里程碑付款的条件，获得一款实验性癌症疗法的授权。</p><p>布尔拉强调：\"中国生物科技公司去年占大型药企药物授权交易总量的近三分之一，这是创新来源地的重大转变。\"他补充称，<a href=\"https://laohu8.com/S/01177\">中国生物制药</a>企业招募临床试验患者的效率可达美国同行的2至5倍。</p></body></html>","source":"stock_zhitongcaijing","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>辉瑞(PFE.US)CEO呼吁：美国制药业需要与中国合作</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n辉瑞(PFE.US)CEO呼吁：美国制药业需要与中国合作\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-10-15 15:00 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1355242.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，辉瑞(PFE.US)首席执行官阿尔伯特·布尔拉周二表示，美国制药业需要与中国制药业开展合作。过去十年间，中国凭借高效的研发流程使其在全球药物研发中的占比跃升至30%。布尔拉在纽约出席美中关系全国委员会晚宴时指出：\"在生物制药领域，中国惊人的速度、成本和规模优势已引发全球竞争格局转变。\"他透露，中国目前拥有约1200种新药候选药物，而十年前这一数字仅为60种。此番表态正值美国总统...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1355242.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","LU0306806265.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" ACC","LU0225771236.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (USD) INC MF","BK4550":"红杉资本持仓","BK4588":"碎股","BK4568":"美国抗疫概念","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","BK4007":"制药","SG9999011175.SGD":"Nikko AM Global Dividend Equity Dis SGD-H","SG9999003800.SGD":"Nikko AM Global Dividend Equity Acc SGD-H","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","LU0321505868.SGD":"Schroder ISF Global Dividend Maximiser A Dis SGD","LU0306807586.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" (USD) INC QF","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","SG9999001176.USD":"United Global Healthcare Acc USD","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","LU0321505439.SGD":"Schroder ISF Global Dividend Maximiser A Acc SGD","LU0985481810.HKD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (HKD) INC M","IE000M9KFDE8.USD":"NEUBERGER BERMAN US LARGE CAP VALUE \"A\" (USD) ACC","BK4592":"伊斯兰概念","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","BK4599":"减肥药","BK4581":"高盛持仓","LU0225284248.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" ACC","LU0058720904.USD":"联博国际健康护理基金A","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","LU1894683264.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) ACC","BK4585":"ETF&股票定投概念","BK4534":"瑞士信贷持仓","SG9999002224.SGD":"Allianz Global High Payout SGD","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","LU1894683348.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) INC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","BK4533":"AQR资本管理(全球第二大对冲基金)","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","LU0122379950.USD":"贝莱德世界健康科学A2","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","LU0234572021.USD":"高盛美国核心股票组合Acc","SG9999002232.USD":"Allianz Global High Payout USD","PFE":"辉瑞","LU1883839398.USD":"AMUNDI FUNDS INCOME OPPORTUNITIES \"A2\" (USD) ACC"},"source_url":"http://www.zhitongcaijing.com/content/detail/1355242.html","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2575513203","content_text":"智通财经APP获悉，辉瑞(PFE.US)首席执行官阿尔伯特·布尔拉周二表示，美国制药业需要与中国制药业开展合作。过去十年间，中国凭借高效的研发流程使其在全球药物研发中的占比跃升至30%。布尔拉在纽约出席美中关系全国委员会晚宴时指出：\"在生物制药领域，中国惊人的速度、成本和规模优势已引发全球竞争格局转变。\"他透露，中国目前拥有约1200种新药候选药物，而十年前这一数字仅为60种。此番表态正值美国总统特朗普对主要经济竞争对手中国实施一系列关税措施之际。这些针对数百亿美元进口商品的关税政策，据称旨在缩小巨额贸易逆差、重振制造业并打击芬太尼贸易。美国众议院去年也曾通过法案试图限制美国企业与中国药企合作。该法案最终未获参议院通过，但今年早些时候已有新版本被重新提交。尽管中美存在贸易摩擦，欧美制药公司仍寄望中国补充其药物研发管线。今年初，辉瑞与中国三生制药达成协议，以12.5亿美元预付款加最高48亿美元里程碑付款的条件，获得一款实验性癌症疗法的授权。布尔拉强调：\"中国生物科技公司去年占大型药企药物授权交易总量的近三分之一，这是创新来源地的重大转变。\"他补充称，中国生物制药企业招募临床试验患者的效率可达美国同行的2至5倍。","news_type":1,"symbols_score_info":{"PFE":1.5}},"isVote":1,"tweetType":1,"viewCount":137,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":20,"optionInvolvedFlag":false,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/489477155615168"}